- Home
- BTMD vs PRLD Comparison
BTMD vs PRLD Comparison
Compare BTMD & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BTMD | PRLD |
|---|---|---|
| Founded | 2012 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 64.4M | 69.1M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | BTMD | PRLD |
|---|---|---|
| Price | $2.09 | $2.76 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $6.00 | $4.00 |
| AVG Volume (30 Days) | 138.6K | ★ 337.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 16.83 |
| EPS | ★ 0.68 | N/A |
| Revenue | ★ $197,191,000.00 | $7,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.37 | N/A |
| P/E Ratio | $3.12 | ★ N/A |
| Revenue Growth | ★ 6.38 | N/A |
| 52 Week Low | $2.02 | $0.61 |
| 52 Week High | $4.75 | $4.19 |
Technical Indicators
Market Signals| Indicator | BTMD | PRLD |
|---|---|---|
| Relative Strength Index (RSI) | 43.18 | 58.17 |
| Support Level | $2.02 | $0.96 |
| Resistance Level | $2.37 | $3.00 |
| Average True Range (ATR) | 0.10 | 0.31 |
| MACD | 0.01 | 0.06 |
| Stochastic Oscillator | 33.33 | 59.12 |
Price Performance
Historical ComparisonAbout BTMD Biote Corp.
Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The company derives revenue from United States and also has its presence in other countries.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.